Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2013

View Archived Issues

Biogen presents novel AAV-virus derived mouse models of neurodegenerative disorders

Clinical data on GS-9973 alone and in combination with idelalisib reported

InDex Pharmaceuticals completes patient recruitment in phase III Kappaproct trial

TP-0413 as therapy for treating anemia of chronic disease

Encouraging phase I study results reported for LPCN-1111

ASP-9133 shows improved potency and selective inhibition of bronchoconstriction

Bavarian Nordic plans interim analysis of PROSPECT trial

GSK and A*STAR's ICES to develop evidence-based formulations

New tool for predicting progression of mild cognitive impairment to Alzheimer's disease

Improving diagnosis via the discovery of biomarker ligands in patients with NMO

Gilead Sciences submits NDA for sofosbuvir

Sarepta reports results from extension study of eteplirsen in Duchenne muscular dystrophy

PredictAD tool proves useful for AD conversion

Viralytics planning phase I/II study of Cavatak following phase I results

EyeGate Pharma reports topline data from phase III study in anterior uveitis

Vaxil BioTherapeutics reports results from phase I/II ImMucin trial

Pfizer to launch Ameparomo for intestinal amebiasis in Japan

Eisai discloses novel chemokine receptor antagonists

Merck & Co. reports novel agents for HCV infection

Scientists at Merck KGaA disclose novel p70S6K inhibitors

Novartis prepares new CFTR activators

RVX-2135 shows promise in AML cell lines

Stem Cell Therapeutics completes merger with Trillium Therapeutics

Lipid Therapeutics files IND for LT-02

Topline results reported from phase II study of RP-5063

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...